Arthur Tzianabos | President and Chief Executive Officer
Homology Medicines

Arthur Tzianabos, President and Chief Executive Officer, Homology Medicines

Arthur Tzianabos brings 25 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. During his nine-year tenure at Shire, he played an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s product pipeline. Dr. Tzianabos joins Homology Medicines from OvaScience where he served as President and CSO and was responsible for translating breakthrough science into new treatments, which included the commercial launch of the company’s first product. Earlier in his career, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters, and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.


World Orphan Drug Congress USA 2018 - Seminars @ 11:20

Next generation in vivo and ex vivo gene editing using homologous recombination to treat rare diseases

World Orphan Drug Congress USA 2018 - Conference Day One @ 17:20

Keynote panel: How rare disease companies are ramping up innovation to boost orphan drug development and patient centricity

  • Incorporating patients in the drug development process and working towards commercial viability- how to fully engage? 
  • How do you view disruptive therapies such as (gene therapy/gene editing) impacting the broader orphan disease development paradigm? How are you innovating within your company?
  • Responding to the changes in the political, regulatory and reimbursement landscape while guiding the direction of rare disease companies 
  • How to achieve industry collaboration and idea exchanges that can better serve the patient community? 

back to speakers